

Product datasheet for TL312742V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

GLUD1 Human shRNA Lentiviral Particle (Locus ID 2746)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: GLUD1 Human shRNA Lentiviral Particle (Locus ID 2746)

Locus ID: 2746

Synonyms: GDH; GDH1; GLUD

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: GLUD1 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001318900, NM 001318901, NM 001318902, NM 001318904, NM 001318905,

NM 001318906, NM 005271, NM 005271.1, NM 005271.3, NM 005271.4, BC112946,

BC112946.1, BC040132, NM 005271.5

UniProt ID: P00367

Summary: This gene encodes glutamate dehydrogenase, which is a mitochondrial matrix enzyme that

catalyzes the oxidative deamination of glutamate to alpha-ketoglutarate and ammonia. This enzyme has an important role in regulating amino acid-induced insulin secretion. It is allosterically activated by ADP and inhibited by GTP and ATP. Activating mutations in this gene are a common cause of congenital hyperinsulinism. Alternative splicing of this gene results in multiple transcript variants. The related glutamate dehydrogenase 2 gene on the human X-chromosome originated from this gene via retrotransposition and encodes a soluble form of glutamate dehydrogenase. Related pseudogenes have been identified on

chromosomes 10, 18 and X. [provided by RefSeq, Jan 2016]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).